TABLE 3.
Dose Reduction, Cycle Delay, and Therapy Completion
| Posology | N | No | Yes | Univariate Analysis* |
|---|---|---|---|---|
| Dose reduction, n (%) | ||||
| Cycle 1 | 173 | 165 (95.4) | 8 (4.6) | 0.390 |
| Cycle 2 | 157 | 152 (96.8) | 5 (3.2) | |
| Cycle 3 | 150 | 150 (98.7) | 2 (1.3) | |
| Cycle 4 | 141 | 137 (97.2) | 4 (2.8) | |
| Sum | 621 | 602 (96.9) | 19 (3.1) | |
| Cycle delay, n (%) | ||||
| Cycle 1 | 173 | 173 (100) | 0 | Not included |
| Cycle 2 | 157 | 145 (92.4) | 12 (7.6) | 0.554 |
| Cycle 3 | 150 | 135 (90.0) | 15 (10.0) | |
| Cycle 4 | 141 | 125 (88.7) | 16 (11.3) | |
| Sum | 621 | 578 (93.1) | 43 (6.9) | |
*
Univariate analysis was performed by the Fisher exact test with statistical significance set at P<0.05. The univariate analysis was used to determine if there was a significant difference in posology use between cycles of therapy.